journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/28097913/cost-consequence-analysis-of-different-active-flowable-hemostatic-matrices-in-cardiac-surgical-procedures
#1
D Makhija, M Rock, Y Xiong, J D Epstein, M R Arnold, O M Lattouf, D Calcaterra
BACKGROUND: A recent retrospective comparative effectiveness study found that use of FLOSEAL® Hemostatic Matrix in cardiac surgery was associated with significantly lower risks of complications, blood transfusions, surgical revisions and shorter length of surgery than use of SURGIFLO(®) Hemostatic Matrix. These outcome improvements in cardiac surgery procedures may translate to economic savings for hospitals and payers. OBJECTIVE: The objective of this study was to estimate the cost-consequence of two flowable hemostatic matrices (FLOSEAL or SURGIFLO) in cardiac surgeries for US hospitals...
January 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28097904/estimated-burden-of-cardiovascular-disease-and-value-based-price-range-for-evolocumab-in-a-high-risk-secondary-prevention-population-in-the-us-payer-context
#2
Peter P Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira, Jeroen P Jansen
AIM: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. MATERIALS AND METHODS: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into 4 cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (N = 1448), acute coronary syndrome (ACS) (N = 602), ischemic stroke (IS) (N = 151), and heart failure (HF) (N = 291) incident cohorts...
January 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28092235/hospital-cost-and-length-of-stay-in-idiopathic-pulmonary-fibrosis
#3
Joshua J Mooney, Karina Raimundo, Eunice Chang, Michael S Broder
OBJECTIVE: To provide a detailed picture of the economic impact of hospitalization in idiopathic pulmonary fibrosis (IPF) and to identify factors associated with cost and length of stay (LOS). METHODS: In this retrospective cross-sectional study using the Nationwide Inpatient Sample (NIS), we included hospitalizations for IPF (ICD-9-CM 516.3) with a principal diagnosis of respiratory disease (ICD-9-CM 460-519) from 2009-2011; lung transplant admissions were excluded...
January 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28092219/the-21st-century-cures-act-pharmacoeconomic-boon-or-bane
#4
Roger Lee Mendoza
Barriers to entry in healthcare markets constitute one of the overriding concerns of health economists. The recent enactment of the 21st Century Cures Act in the United States is one landmark legislation that reduces statutory entry barriers to the discovery, development, testing and licensing of drugs and medical devices. However, it brings with it many critical challenges concerning the safety, efficacy and value of drugs and devices, along with novel opportunities for medical innovation and faster treatment of diseases...
January 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28058859/clinical-characteristics-treatment-patterns-and-socio-economic-burden-of-copd-in-bulgaria
#5
Maria Kamusheva, Maria Dimitrova, Job Fm van Boven, Maarten J Postma, Thys van der Molen, Janwillem Wh Kocks, Konstantin Mitov, Miglena Doneva, Daniela Petrova, Ognyan Georgiev, Valentina Petkova, Guenka Petrova
INTRODUCTION: While the impact of COPD in Western-Europe is known, data from Eastern-Europe is scarce. We aimed to evaluate clinical characteristics, treatment patterns and the socio-economic burden of COPD in Eastern-Europe, taking Bulgaria as a reference case. METHODS: A representative sample of Bulgarian patients with COPD was randomly chosen by pulmonologists based on the following inclusion criteria: COPD diagnosis with at least one year of living with COPD, ≥40 years of age, and use of COPD medication...
January 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#6
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28035846/employment-and-absenteeism-in-working-age-persons-with-multiple-sclerosis
#7
Amber Salter, Nina Thomas, Tuula Tyry, Gary Cutter, Ruth Ann Marrie
AIMS: To better understand the impact of the clinical course of multiple sclerosis (MS) and disability on employment, absenteeism, and related factors. MATERIALS AND METHODS: We included respondents to the North American Research Committee on Multiple Sclerosis Registry spring 2015 update survey who were United States or Canadian residents, aged 18-65 years and reported having relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS)...
December 30, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28035843/within-the-triangle-of-healthcare-legacies-comparing-the-performance-of-south-eastern-european-health-systems
#8
Mihajlo Michael Jakovljevic, Jelena Arsenijevic, Milena Pavlova, Nick Verhaeghe, Ulrich Laaser, Wim Groot
OBJECTIVE: Inter-regional comparison of health-reform outcomes in south-eastern Europe (SEE). METHODS: Macro-indicators were obtained from the WHO Health for All Database. Inter-regional comparison among post-Semashko, former Yugoslavia and prior-1989-free-market SEE economies was conducted. RESULTS: United Nations Development Program Human Development Index growth was strongest among prior-free-market SEE followed by former Yugoslavia and post-Semashko...
December 30, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008770/the-budget-impact-and-cost-effectiveness-of-defibrotide-for-treatment-of-veno-occlusive-disease-with-multi-organ-dysfunction-in-patients-post-hematopoietic-stem-cell-transplant
#9
David L Veenstra, Gregory F Guzauskas, Kathleen F Villa, Denise M Boudreau
BACKGROUND: A Phase-3 study of defibrotide compared with historical controls demonstrated a 23% improvement in 100-day survival post-hematopoietic stem cell transplantation (HSCT) among patients with veno-occlusive disease with multi-organ dysfunction (VOD with MOD). AIM: To estimate the budget impact and cost-effectiveness of introducing defibrotide to a transplant center. METHODS: We developed a budget impact model from the perspective of a bone-marrow transplant center...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008769/a-discrete-event-simulation-to-model-the-cost-utility-of-fingolimod-and-natalizumab-in-rapidly-evolving-severe-relapsing-remitting-multiple-sclerosis-in-the-uk
#10
Stephen Montgomery, Maciej Maruszczak, David Slater, Jeanette Kusel, Richard Nicholas, Nicholas Adlard
OBJECTIVE: Two disease modifying therapies are licensed in the EU for use in rapidly-evolving severe (RES) relapsing-remitting multiple sclerosis (RRMS), fingolimod and natalizumab. Here a discrete event simulation (DES) model to analyse the cost-effectiveness of natalizumab and fingolimod in the RES population, from the perspective of the National Health Service (NHS) in the UK, is reported. METHODS: A DES model was developed to track individual RES patients, based on Expanded Disability Status Scale scores...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/28008768/the-cost-effectiveness-of-dulaglutide-versus-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-spain-in-patients-with-bmi%C3%A2-30%C3%A2-kg-m-2
#11
Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, Ruba Ayyub, Julia Lowin, Kirsi Norrbacka
OBJECTIVE: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 (GLP-1) receptor agonist, for the treatment of type two diabetes mellitus (T2DM). The objective was to estimate the cost-effectiveness of dulaglutide once weekly versus liraglutide 1.8mg once daily for the treatment of T2DM in Spain in patients with a BMI≥30 kg/m(2). METHODS: The IMS CORE Diabetes Model (CDM) was used to estimate costs and outcomes from the perspective of Spanish National Health System, capturing relevant direct medical costs over a lifetime time horizon...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27926814/the-economic-impact-of-insulin-related-hypoglycemia-in-denmark-an-analysis-using-the-local-impact-of-hypoglycemia-tool
#12
Nicki Hoskins, Christian Klyver Tikkanen, Ulrik Pedersen-Bjergaard
AIMS: To estimate the direct cost of hypoglycemia in insulin-treated adults with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in Denmark. MATERIALS AND METHODS: The Local Impact of Hypoglycemia Tool (LIHT) was used to estimate the costs associated with insulin-related hypoglycemia. Average utilization of healthcare resources, including the costs of pre-hospitalization, hospital admission, healthcare professional contact and follow-up, glucose/glucagon, and extra SMBG tests to monitor blood glucose following an episode, was used to calculate an average cost per severe and per non-severe hypoglycemic episode...
December 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27919186/economic-evaluation-for-the-us-of-nab-paclitaxel-plus-gemcitabine-versus-folfirinox-versus-gemcitabine-in-the-treatment-of-metastatic-pancreas-cancer
#13
Mahdi Gharaibeh, Ali McBride, J Lyle Bootman, Hitendra Patel, Ivo Abraham
BACKGROUND: Nab-paclitaxel plus gemcitabine (NAB-P + GEM) and FOLFIRINOX have shown superior efficacy over gemcitabine (GEM) in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDA). Although the incremental clinical benefits are modest, both treatments represent significant advances in the treatment of a high-mortality cancer. In this independent economic evaluation for the US, the aim was to estimate the comparative cost-utility and cost-effectiveness of these three regimens from the payer perspective...
December 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27885871/continuous-prophylaxis-with-recombinant-factor-ix-fc-fusion-protein-and-conventional-recombinant-factor-ix-products-comparisons-of-efficacy-and-weekly-factor-consumption
#14
Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Sander Yermakov, Paul Karner
BACKGROUND: Continuous prophylaxis for patients with hemophilia B requires frequent injections that are burdensome and that may lead to suboptimal adherence and outcomes. Hence, therapies requiring less-frequent injections are needed. In the absence of head-to-head comparisons, this study compared the first extended-half-life-recombinant factor IX (rFIX) product-recombinant factor IX Fc fusion protein (rFIXFc)-with conventional rFIX products based on annualized bleed rates (ABRs) and factor consumption reported in studies of continuous prophylaxis...
December 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27998195/healthcare-utilization-and-costs-in-patients-with-tuberous-sclerosis-complex-related-renal-angiomyolipoma
#15
Xue Song, Zhimei Liu, Katherine Cappell, Christopher Gregory, Qayyim Said, Judith Prestifilippo, Hearns Charles, John Hulbert, John Bissler
OBJECTIVE: To quantify healthcare utilization and costs in patients with tuberous sclerosis complex (TSC) and renal angiomyolipoma in a matched cohort of patients without TSC or angiomyolipoma. METHODS: Administrative data from the MarketScan® Research Databases were used to select patients with TSC and renal angiomyolipoma during 1/1/2000-3/31/2013 from the Commercial database and 1/1/2000-6/30/2012 from the Medicaid database. Patients were required to have at least 30 days of follow-up from initiation into the study, and were followed until inpatient death, end of insurance coverage, or the end of study...
December 20, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27981865/healthcare-resource-utilization-in-patients-receiving-idarucizumab-for-reversal-of-dabigatran-anticoagulation-due-to-major-bleeding-urgent-surgery-or-procedural-interventions-interim-results-from-the-re-verse-ad-%C3%A2-study
#16
Charles V Pollack, Richard Bernstein, Robert Dubiel, Paul Reilly, Fredrik Gruenenfelder, Menno V Huisman, Chak-Wah Kam, Eva Kleine, Jerrold H Levy, Frank W Sellke, Thorsten Steiner, Anastasia Ustyugova, Jeffrey I Weitz
AIMS: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate. MATERIALS AND METHODS: RE-VERSE AD(™) (NCT02104947), a prospective, multicenter open-label study is evaluating idarucizumab for dabigatran reversal in patients with serious bleeding (Group A) or undergoing emergency surgery/procedures (Group B)...
December 16, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27981858/budget-impact-of-everolimus-for-the-treatment-of-progressive-well-differentiated-non-functional-neuroendocrine-tumors-of-gastrointestinal-or-lung-origin-that-are-advanced-or-metastatic
#17
Darya B Rose, Dave Nellesen, Maureen P Neary, Beilei Cai
BACKGROUND: Advanced neuroendocrine tumors (NETs) are a rare malignancy with considerable need for effective therapies. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2016 for treatment of adults with progressive, well-differentiated, non-functional NETs of gastrointestinal (GI) or lung origin that are unresectable, locally advanced, or metastatic. OBJECTIVE: To assess the 3-year budget impact for a typical US health plan following availability of everolimus for treatment of GI and lung NETs...
December 16, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27937141/the-impact-of-medical-insurance-coverage-and-molecular-monitoring-frequency-on-outcomes-in-chronic-myeloid-leukemia-real-world-evidence-in-china
#18
Guangying Sheng, Suning Chen, Ri Zhang, Miao Miao, Wu Depei, Seng Chuen Tan, Chao Liu, Tengbin Xiong
OBJECTIVES: Imatinib (Glivec) has been covered by critical disease insurance for treatment of chronic myeloid leukemia (CML) in Jiangsu province of China since 2013. Further, free molecular monitoring has been provided to patients at top clinical centers as part of a pilot that has changed the local treatment pattern and outcomes of patients with CML. This study evaluates the impact of medical insurance coverage and the molecular monitoring frequency on outcomes of patients with CML treated at a central hospital in Jiangsu of China according to patient-level data...
December 10, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27936995/societal-implications-of-medical-insurance-coverage-for-imatinib-as-first-line-treatment-of-chronic-myeloid-leukemia-in-china-a-cost-effectiveness-analysis
#19
Guangying Sheng, Suning Chen, Chaohui Dong, Ri Zhang, Miao Miao, Wu Depei, Seng Chuen Tan, Chao Liu, Tengbin Xiong
OBJECTIVES: Imatinib (Glivec) and nilotinib (Tasigna) have been covered by critical disease insurance in Jiangsu province of China since 2013, which changed local treatment patterns and outcomes of patients with chronic myeloid leukemia (CML). This study evaluated the long-term cost-effectiveness of insurance coverage with imatinib as the first-line treatment for patients with CML in China from a societal perspective. METHODS: A decision-analytic model based on previously published and real-world evidence was applied to simulate and evaluate the lifetime clinical and economic outcomes associated with CML treatments before and after imatinib was covered by medical insurance...
December 10, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27919177/economic-burden-of-inadequate-symptom-control-among-us-commercially-insured-irritable-bowel-syndrome-patients-with-diarrhea
#20
Jessica L Buono, Kush Mathur, Amelia J Averitt, David A Andrae
AIMS: To assess healthcare resource use and costs among irritable bowel syndrome (IBS) with diarrhea (IBS-D) patients with and without evidence of inadequate symptom control on current prescription therapies and estimate incremental all-cause costs associated with inadequate symptom control. METHODS: IBS-D patients aged ≥18 years with ≥1 medical claim for IBS (ICD-9-CM 564.1x) and either ≥2 claims for diarrhea (ICD-9-CM 787.91, 564.5x), or ≥1 claim for diarrhea plus ≥1 claim for abdominal pain (ICD-9-CM 789...
December 6, 2016: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"